SIC
ESPR

SJS Investment Consulting’s Esperion Therapeutics ESPR Stock Holding History

SJS Investment Consulting’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,000
Closed -$68.5K – 2917
2026
Q1 		$68.5K Hold
25,000
– – 0.01% 281
2025
Q4 		$92.5K Hold
25,000
– – 0.01% 218
2025
Q3 		$66.3K Hold
25,000
– – 0.01% 227
2025
Q2 		$24.6K Hold
25,000
– – ﹤0.01% 258
2025
Q1 		$36K Hold
25,000
– – 0.01% 227
2024
Q4 		$55K Buy
+25,000
New +$58.3K 0.01% 176

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

SJS Investment Consulting's ESPR Position: Q2 2026 in Review

SJS Investment Consulting sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 25,000 shares — an estimated $68.5K sold.

SJS Investment Consulting first reported a position in ESPR in Q4 2024 and held it in 6 quarters. The position peaked at $92.5K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • SJS Investment Consulting reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SJS Investment Consulting sold 25,000 Esperion Therapeutics shares in Q2 2026, an estimated $68.5K.
  • SJS Investment Consulting first reported a position in Esperion Therapeutics in Q4 2024 and held it in 6 quarters.
  • SJS Investment Consulting's Esperion Therapeutics position peaked at $92.5K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.